# Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

> **NCT07674745** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 52 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **OTHER:** Therapeutic Plasma Exchange
- **DRUG:** Rituximab
- **DRUG:** Intravenous immunoglobulin
- **DRUG:** Treatment as Usual

## Key facts

- **NCT ID:** NCT07674745
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2030-09-30
- **Final completion:** 2031-03-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674745, "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*